Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Lilly is studying retatrutide in several Phase 3 clinical trials to evaluate its potential efficacy and safety in obesity and type-2 diabetes, along with other adjacent comorbidities including knee osteoarthritis pain, moderate-to-severe OSA, chronic low back pain, metabolic dysfunction-associated steatotic liver disease and several others.
Alpha lipoic acid enhances the level of L-glutathione in the body
Coverage for weight loss is available in approximately 14 states, though with strict requirements
Retatrutide offers dramatically greater weight loss, extraordinary liver fat reduction, and a triple-receptor mechanism that represents the cutting edge of metabolic pharmacology, but with higher side effect rates, no long-term safety data, and no current regulatory approval
US$ 20.07
US$ 22.45
US$ 28.95
US$ 27.08
US$ 21.91
US$ 28.45
